CCR8 Antibody (YA1373)

CCR8 (C-C chemokine receptor 8) is a class A G protein-coupled chemokine receptor that primarily mediates immune-cell trafficking through interactions with the endogenous ligand CCL1, thereby regulating leukocyte migration, inflammatory positioning, and immune-cell survival programs^[1][2]. Mechanistically, structural studies demonstrate that CCL1 activates CCR8 through a two-step binding process involving receptor extracellular domains and subsequent signaling activation, providing a molecular framework for CCR8-dependent chemotaxis and immune regulation^[1]. In disease-associated tissues, CCR8 is highly enriched on suppressive intratumoral regulatory T cells and is linked to immunosuppressive tumor microenvironments, making CCR8 a relevant target for cancer immunology research and therapeutic intervention studies^[1][3]. Experimental evidence further indicates that CCR8 signaling interacts with innate immune pathways, including Toll-like receptor 4 signaling, supporting a broader role in inflammatory regulation beyond chemokine-directed cell migration^[4]. Compared with related chemokine receptors such as CCR4, which recognizes multiple ligands including CCL17 and CCL22, CCR8 displays a more restricted ligand profile centered on CCL1-mediated signaling, supporting its utility as a comparatively selective immunological target^[1][2]. For experimental applications, both antagonistic antibodies and synthetic CCR8 agonists or antagonists have been developed to investigate receptor activation mechanisms, ligand bias, and immune-cell functions in cancer and inflammatory disease models^[1][2].